Sign In
Buy BBIO
$65.48
+1.60 (+2.50%)
At Close: Jun 03, 2026
Pharma Stock Soars on Heart Disease Drug Trial
10:52am, Monday, 17'th Jul 2023
BridgeBio Pharma Inc (NASDAQ:BBIO) stock is one of the best stocks on Wall Street today, after the pharma name's heart disease drug, acoramidis, met the main goal in a late-stage study.
Why Is BridgeBio (BBIO) Stock Up 63% Today?
10:04am, Monday, 17'th Jul 2023
BridgeBio Pharma (NASDAQ: BBIO ) stock is climbing higher on Monday as investors react to results from a Phase 3 clinical trial. These results come from the company's ATTRibute-CM study of acoramidis
BridgeBio's stock rockets 66% on news of positive results from late-stage trial of ATTR-CM treatment
07:32am, Monday, 17'th Jul 2023
BridgeBio Pharma Inc.'s stock BBIO, +5.26% rocketed 66% in premarket trade Monday, after the company announced positive results in a late-stage trial of a treatment for transthyretin amyloid cardiomyo
2 Nasdaq Stocks That Could Soar This Week
08:00pm, Sunday, 16'th Jul 2023
BridgeBio Pharma is slated to announce late-stage results for an important pipeline candidate on Monday. Roivant Sciences might be close to a major asset sale that could spark a hefty rally in its sha
Andreas Halvorsen Curbs Roivant Sciences Stake
05:53pm, Tuesday, 27'th Jun 2023
Andreas Halvorsen (Trades, Portfolio), the chief investment officer of Viking Global Investors, disclosed earlier this week he reduced his stake in Roivant Sciences Ltd. ( ROIV , Financial) by 14.73%.
2 Growth Stocks With Major Incoming Catalysts
05:31am, Tuesday, 27'th Jun 2023
BridgeBio stock collapsed when acoramidis failed a pivotal trial, but follow-up data on the way could allow the program, and the stock, to redeem itself. Biohaven shares could shoot higher if the U.S.
BridgeBio Pharma shares gain on trial results for dwarfism drug
08:48am, Tuesday, 20'th Jun 2023
Shares of BridgeBio Pharma Inc. BBIO, -3.29% gained 5.5% premarket on Tuesday after the company announced that its investigational treatment for children with achondroplasia, a bone growth disorder th
Why BridgeBio Pharma Stock Is Plunging Today
02:04pm, Thursday, 15'th Jun 2023
JPMorgan cautioned investors ahead of a key clinical readout for BridgeBio this coming July. As a result, the biotech's stock is falling today.
PALO ALTO, Calif., June 08, 2023 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage biopharmaceutical company focused on genetic dise
PALO ALTO, Calif., May 15, 2023 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage biopharmaceutical company focused on genetic disea
BridgeBio Pharma: A Lot Of Paths To Potential Success
06:29am, Monday, 15'th May 2023
We put BridgeBio Pharma, Inc. in the spotlight for the first time since last summer as the company continues to have buyout speculation around it. BridgeBio also has had some positive recent trial dev
BridgeBio Pharma to Participate in the Bank of America Merrill Lynch Global Healthcare Conference
07:30am, Thursday, 27'th Apr 2023
PALO ALTO, Calif., April 27, 2023 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage biopharmaceutical company focused on genetic dise
The 5 Best- and Worst-Performing Mid-Cap Stocks in March 2023
10:58pm, Monday, 10'th Apr 2023
March was a good month for the stock market, with the S&P 500 gaining about 3.5%.
2 Best Growth Stocks to Buy in April
10:00am, Monday, 03'rd Apr 2023
Growth stocks have been under heavy pressure over the past year. A handful of biotech companies have defied this broader downturn, however.
Bridgebio shares surge on takeout target hopes
03:14pm, Wednesday, 29'th Mar 2023
CNBC's Meg Tirrell joins 'Power Lunch' to report on Bridgebio's stock surge and pharma returns.
